From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
June 27, 2023
Philadelphia, PA, June 27, 2023 – Blue Fin Group, a management consulting firm to the Life Sciences industry, today announced the promotion of seasoned industry advisor Jason Bogroff to partner. In his new role, Bogroff will have direct client responsibility and will lead the firm’s Data Strategy area of focus. He joins the partner team as Blue Fin Group is expanding its role as a consulting firm within IntegriChain. One of the original advisors to many of the data analytics companies that operate in Life Sciences, today Bogroff is highly sought after for his vision in business strategy across product, pharmacy, payer, patient, and distribution as well as for his ability to apply the insights from data to optimize net revenues and the patient journey.
“Jason’s career has been amazing to watch,” said Bill Roth, Senior Vice President of Consulting. “He’s a consummate overachiever and a gifted consultant. While at Blue Fin Group he gained his master’s degree from The Wharton School + UPenn Engineering while proving to be a pivotal member of the company. He is a unique visionary who doesn’t think outside the box; to Jason, there was never a box in the first place. While he’s versed in all aspects of commercialization, Jason’s real passion is data strategy. With his background in engineering, he is outstanding at discovering insights, optimizing business processes, and unlocking competitive advantage, and as a serial entrepreneur, he understands the challenges navigating headwinds life sciences manufacturers now and into the future. Given the role we play as management consultants, I can’t wait to see what Jason’s next chapter as a Blue Fin Group partner looks like.”
About Jason BogroffBogroff joined Blue Fin Group in 2006. During his tenure, he has led the development of Blue Fin Group’s proprietary consulting methodology. He has worked across the spectrum of Life Sciences commercialization in pharmaceuticals, medical devices, and consumer health. He was on the leading edge of Specialty Channel and Patient Services Strategy and Commercial Data back in the late 2000s and has maintained his frontline position. Bogroff earned a Bachelor of Science degree in Chemical Engineering from Michigan State University and a Master of Science degree with an Executive Master’s in technology management from the University of Pennsylvania.
About Blue Fin Group, an IntegriChain CompanyBlue Fin Group develops strategies to optimize patient access, commercialization, and gross-to-net to support Life Sciences manufacturers throughout the product life cycle. Blue Fin Group is a full-service management consulting firm delivering research, strategy, and implementation to help manufacturers align all the elements of marketing, market access, field sales, pharmacy and distribution, and patient services as a seamless commercial strategy that helps optimize patient outcomes. Blue Fin Group has served more than 300 manufacturers ranging from those commercializing their first asset to large global firms with products that span cell and gene therapies, orphan/rare, specialty, primary care, vaccines, biosimilars, and generics. For additional information, visit https://consultbfg.com/ or follow on LinkedIn.
ContactJennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List